Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) is of particular importance in cholesterol metabolism with high levels contributing to hypercholesterolemia. Cholesterol and sphingolipids are low in patients with liver cirrhosis. Purpose of this study was to find associations of plasma PCSK9 with circulating cholesterol and sphingolipid species and measures of liver disease severity in patients with liver cirrhosis. Methods PCSK9 protein levels were determined by ELISA in systemic vein (SVP), hepatic vein (HVP) and portal vein plasma of patients with mostly alcoholic liver cirrhosis. PCSK9 and LDL-receptor protein expression were analysed in cirrhotic and non-cirrhotic liver tissues. Results Serum PCSK9 was reduced ...
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) associates with cardiovascular disease indepen...
Introduction: Nonalcoholic fatty liver disease (NAFLD) is the leading cause of liver damage and asso...
Background: Proprotein convertase subtilisin/Kexin type 9 (PCSK-9) inhibitors induced liver dysfunct...
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) is of particular importance in cho...
BACKGROUND Proprotein convertase subtilisin/kexin type 9 (PCSK9) is of particular importance in c...
Chronic liver diseases are commonly associated with dysregulated cholesterol metabolism. Proprotein ...
Direct-acting antivirals (DAAs) efficiently eradicate the hepatitis C virus (HCV). Low-density lipop...
<div><p>Introduction</p><p>Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in the cholesterol metabolism...
ABSTRACT Background: In parallel to the increasing prevalence of metabolic syndrome, the prevalence ...
Background: Since emerging evidence suggests a protective role of proprotein convertase subtilisin/k...
Introduction: Anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies have been very e...
IF 4.467 (2017)International audienceBackground and aimsSome studies suggested that proprotein conve...
Non-alcoholic fatty liver disease (NAFLD) is becoming the main cause of liver disease in Western cou...
Direct-acting antivirals (DAAs) efficiently eradicate the hepatitis C virus (HCV). Low-density lipop...
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) associates with cardiovascular disease indepen...
Introduction: Nonalcoholic fatty liver disease (NAFLD) is the leading cause of liver damage and asso...
Background: Proprotein convertase subtilisin/Kexin type 9 (PCSK-9) inhibitors induced liver dysfunct...
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) is of particular importance in cho...
BACKGROUND Proprotein convertase subtilisin/kexin type 9 (PCSK9) is of particular importance in c...
Chronic liver diseases are commonly associated with dysregulated cholesterol metabolism. Proprotein ...
Direct-acting antivirals (DAAs) efficiently eradicate the hepatitis C virus (HCV). Low-density lipop...
<div><p>Introduction</p><p>Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in the cholesterol metabolism...
ABSTRACT Background: In parallel to the increasing prevalence of metabolic syndrome, the prevalence ...
Background: Since emerging evidence suggests a protective role of proprotein convertase subtilisin/k...
Introduction: Anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies have been very e...
IF 4.467 (2017)International audienceBackground and aimsSome studies suggested that proprotein conve...
Non-alcoholic fatty liver disease (NAFLD) is becoming the main cause of liver disease in Western cou...
Direct-acting antivirals (DAAs) efficiently eradicate the hepatitis C virus (HCV). Low-density lipop...
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) associates with cardiovascular disease indepen...
Introduction: Nonalcoholic fatty liver disease (NAFLD) is the leading cause of liver damage and asso...
Background: Proprotein convertase subtilisin/Kexin type 9 (PCSK-9) inhibitors induced liver dysfunct...